Compare VELO & WHWK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VELO | WHWK |
|---|---|---|
| Founded | 2014 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 102.9M | 95.2M |
| IPO Year | N/A | N/A |
| Metric | VELO | WHWK |
|---|---|---|
| Price | $11.06 | $3.01 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $18.00 | $7.00 |
| AVG Volume (30 Days) | ★ 2.5M | 114.9K |
| Earning Date | 03-16-2026 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $49,158,000.00 | $14,384,000.00 |
| Revenue This Year | $11.94 | N/A |
| Revenue Next Year | $56.44 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 59.44 | N/A |
| 52 Week Low | $1.43 | $1.39 |
| 52 Week High | $23.84 | $3.77 |
| Indicator | VELO | WHWK |
|---|---|---|
| Relative Strength Index (RSI) | 42.00 | 62.01 |
| Support Level | $11.12 | $2.72 |
| Resistance Level | $15.89 | $2.89 |
| Average True Range (ATR) | 2.32 | 0.19 |
| MACD | -0.50 | 0.00 |
| Stochastic Oscillator | 1.52 | 89.53 |
Velo3D Inc provides additive manufacturing (AM), also referred to as three-dimensional printing (3D printing), to deliver breakthroughs in performance, cost, and time in the production of high-value metal parts. The Velo3D intelligent metal additive manufacturing solution is comprised of the Velo3D Flow intelligent print preparation software, the Sapphire production system, and Velo3D Assure, real-time quality assurance software. Its complete manufacturing solution enables clients to build the parts needed, speed their development, and reduce their product costs.
Whitehawk Therapeutics Inc is a preclinical stage oncology therapeutics. The company is engaged in applying technologies to established tumor biology to efficiently deliver improved cancer treatments. The company's three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers.